Citius Oncology (CTOR) Q4 2025 earnings summary

Executive summary

• Transitioned to a revenue-generating company with the U.S. launch of LYMPHIR, a novel immunotherapy for relapsed or refractory Stage I-III CTCL, in December 2025.

• Established distribution agreements with major U.S. wholesalers and initiated international access in 19 markets via Named Patient Programs.

• Leveraged AI-driven analytics to optimize commercial targeting and field execution for LYMPHIR.

• Announced promising preliminary results from a Phase I trial combining pembrolizumab and LYMPHIR in recurrent solid tumors.

Financial highlights

• Cash and cash equivalents stood at $3.9 million as of September 30, 2025.

• Raised $36 million in gross proceeds from strategic financings, including $18 million in December 2025, $9 million in September 2025, and $9 million in July 2025.

• R&D expenses increased to $6.4 million for FY 2025 from $4.9 million in FY 2024.

• G&A expenses rose to $8.8 million from $8.1 million year-over-year.

• Net loss widened to $24.8 million, or ($0.34) per share, compared to $21.1 million, or ($0.31) per share, in the prior year.

Outlook and guidance

• Management estimates the initial U.S. market for LYMPHIR exceeds $400 million and is underserved by current therapies.

• Plans to expand international access and leverage intellectual property protections for competitive positioning.